RBM20 and ischemic cardiomyopathy: In light of these findings, the 2022 ESC guidelines recommend an ICD in patients with non‐ischemic cardiomyopathy and left ventricular dysfunction (LVEF <50%) who have ≥2 of the following 4 risks: (1) syncope, (2) LGE on CMR, (3) monomorphic VT induced during electrophysiological study (EPS), and (4) pathogenic mutations of the LMNA/phospholamban [PLN]/filamin C [FLNC]/RNA binding motif protein 20 [RBM20] genes.40